Erratum to: Curr Behav Neurosci Rep (2015) 2:198–208
DOI 10.1007/s40473-015-0050-5
Subunit-Selective (NR2B) NMDA Receptor Antagonists
The NMDA receptor complex is a tetramer composed of two GluN1 (NR1) subunits and two GluN2 (NR2) subunits. The pharmacological and biophysical properties of the NMDA receptor are largely controlled by the NR2 subunit [44]. Glutamate binds to NR2 while glycine or D-serine binds to the NR1 and NR3 subunits [45, 46]. In an in vivo study of GluN2B knockout in cortical principal neurons, mice exhibited resilient-like behaviors in the tail suspension and elevated plus maze tests [47]. Interestingly, a statistically significant difference in the rs1805502 polymorphism was noted within GRIN2B, the gene encoding GluN2B (NR2B), in a study looking at 178 subjects with TRD, 612 subjects with non-TRD, and 779 healthy controls [48]. Several NR2B subunit selective antagonists (reviewed below) have been explored in the treatment of MDD.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s40473-015-0050-5.
Rights and permissions
About this article
Cite this article
Park, M., Niciu, M.J. & Zarate, C.A. Erratum to: Novel Glutamatergic Treatments for Severe Mood Disorders. Curr Behav Neurosci Rep 3, 86 (2016). https://doi.org/10.1007/s40473-016-0069-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40473-016-0069-2